Sakar Healthcare has significantly expanded its EU market reach, securing two new Marketing Authorizations (MAs) for oncology injections, taking its total to four.

These approvals for Carboplatin and Docetaxel broaden its anti-cancer portfolio for treating ovarian, lung, and other solid tumors.

This strategic move paves the way for wider exports of critical oncology products to Europe.

Sakar is actively preparing for commercial supply, leveraging its advanced EU GMP-approved manufacturing facility and anticipating more MA grants soon.